Pulmoner Vasküler Hastalık

M. Humbert et al., “2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension,” Eur Heart J, vol. 43, no. 38, pp. 3618–3731, 2022, doi: 10.1093/EURHEARTJ/EHAC237.

G. Kovacs, A. Olschewski, A. Berghold, and H. Olschewski, “Pulmonary vascular resistances during exercise in normal subjects: a systematic review,” European Respiratory Journal, vol. 39, no. 2, pp. 319–328, Jan. 2012, doi: 10.1183/09031936.00008611.

B. A. Maron et al., “Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study,” Lancet Respir Med, vol. 8, no. 9, pp. 873–884, Sep. 2020, doi: 10.1016/S2213-2600(20)30317-9.

P. Xanthouli et al., “Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension,” Ann Rheum Dis, vol. 79, no. 3, pp. 370–378, Mar. 2020, doi: 10.1136/ANNRHEUMDIS-2019-216476.

B. Pieske et al., “How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC),” Eur Heart J, vol. 40, no. 40, pp. 3297–3317, Oct. 2019, doi: 10.1093/EURHEARTJ/EHZ641.

K. Zeder et al., “Diagnostic, prognostic and differential-diagnostic relevance of pulmonary haemodynamic parameters during exercise: a systematic review,” European Respiratory Journal, vol. 60, no. 4, Oct. 2022, doi: 10.1183/13993003.03181-2021.

A. P. Fishman, “CLINICAL CLASSIFICATION OF PULMONARY HYPERTERNSION,” Clin Chest Med, vol. 22, no. 3, pp. 385–391, Sep. 2001, doi: 10.1016/S0272-5231(05)70278-1.

G. Simonneau et al., “Clinical classification of pulmonary hypertension,” J Am Coll Cardiol, vol. 43, no. 12 SUPPL., pp. S5–S12, Jun. 2004, doi: 10.1016/J.JACC.2004.02.037.

G. Simonneau et al., “Updated Clinical Classification of Pulmonary Hypertension,” J Am Coll Cardiol, vol. 54, no. 1 SUPPL. 1, Jun. 2009, doi: 10.1016/J.JACC.2009.04.012.

G. Simonneau et al., “Haemodynamic definitions and updated clinical classification of pulmonary hypertension,” European Respiratory Journal, vol. 53, no. 1, Jan. 2019, doi: 10.1183/13993003.01913-2018.

L. Leber, A. Beaudet, and A. Muller, “Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review,” Pulm Circ, vol. 11, no. 1, pp. 1–12, Jan. 2021, doi: 10.1177/2045894020977300.

E. M. T. Lau, E. Giannoulatou, D. S. Celermajer, and M. Humbert, “Epidemiology and treatment of pulmonary arterial hypertension,” Nature Reviews Cardiology 2017 14:10, vol. 14, no. 10, pp. 603–614, Jun. 2017, doi: 10.1038/nrcardio.2017.84.

“Textbook of Pulmonary Vascular Disease,” Textbook of Pulmonary Vascular Disease, 2011, doi: 10.1007/978-0-387-87429-6.

Y.-S. Li et al., “The Ras-JNK Pathway Is Involved in Shear-Induced Gene Expression,” Mol Cell Biol, vol. 16, no. 11, pp. 5947–5954, Nov. 1996, doi: 10.1128/MCB.16.11.5947.

S. Lehoux and A. Tedgui, “Cellular mechanics and gene expression in blood vessels,” J Biomech, vol. 36, no. 5, pp. 631–643, May 2003, doi: 10.1016/S0021-9290(02)00441-4.

M. Rabinovitch et al., “Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension. A correlation of light with scanning electron microscopy and transmission electron microscopy.,” Lab Invest, vol. 55, no. 6, pp. 632–653, Dec. 1986, Accessed: Dec. 04, 2024. [Online]. Available: https://europepmc.org/article/med/3784535

Y. S. J. Li, J. H. Haga, and S. Chien, “Molecular basis of the effects of shear stress on vascular endothelial cells,” J Biomech, vol. 38, no. 10, pp. 1949–1971, Oct. 2005, doi: 10.1016/J.JBIOMECH.2004.09.030.

B. Meyrick and L. Reid, “Ultrastructural findings in lung biopsy material from children with congenital heart defects,” Am J Pathol, vol. 101, no. 3, p. 527, 1980, Accessed: Dec. 04, 2024. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC1903649/

Eisenmenger V., “Die angeborenen Defecte der Kammer scheidewand des Herzens.,” Z Klin Med., vol. 32, pp. 1–28, 1897.

A. C. M. J. Van Riel et al., “Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification,” Int J Cardiol, vol. 174, no. 2, pp. 299–305, Jun. 2014, doi: 10.1016/J.IJCARD.2014.04.072.

B. S. Lowe, J. Therrien, R. Ionescu-Ittu, L. Pilote, G. Martucci, and A. J. Marelli, “Diagnosis of Pulmonary Hypertension in the Congenital Heart Disease Adult Population: Impact on Outcomes,” J Am Coll Cardiol, vol. 58, no. 5, pp. 538–546, Jul. 2011, doi: 10.1016/J.JACC.2011.03.033.

A. J. Marelli, R. Ionescu-Ittu, A. S. Mackie, L. Guo, N. Dendukuri, and M. Kaouache, “Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010,” Circulation, vol. 130, no. 9, pp. 749–756, 2014, doi: 10.1161/CIRCULATIONAHA.113.008396/-/DC1.

J. T. Granton and M. Rabinovitch, “Pulmonary arterial hypertension in congenital heart disease,” Cardiol Clin, vol. 20, no. 3, pp. 441–457, Aug. 2002, doi: 10.1016/S0733-8651(02)00017-6/ASSET/6A88E448-C700-4062-B479-977F6DB7F728/MAIN.ASSETS/GR6.SML.

S. Chien, S. Li, and J. Y. J. Shyy, “Effects of mechanical forces on signal transduction and gene expression in endothelial cells,” Hypertension, vol. 31, no. 1 Pt 2, pp. 162–169, 1998, doi: 10.1161/01.HYP.31.1.162.

M. Rabinovitch, “Elastase and the Pathobiology of Unexplained Pulmonary Hypertension,” Chest, vol. 114, no. 3, pp. 213S-224S, Sep. 1998, doi: 10.1378/CHEST.114.3_SUPPLEMENT.213S.

N. Boudreau, E. Turley, and M. Rabinovitch, “Fibronectin, hyaluronan, and a hyaluronan binding protein contribute to increased ductus arteriosus smooth muscle cell migration,” Dev Biol, vol. 143, no. 2, pp. 235–247, Feb. 1991, doi: 10.1016/0012-1606(91)90074-D.

P. L. Jones, K. N. Cowan, and M. Rabinovitch, “Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease,” Am J Pathol, vol. 150, no. 4, p. 1349, 1997, Accessed: Dec. 04, 2024. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC1858188/

M. Yoshibayashi et al., “Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation.,” Circulation, vol. 84, no. 6, pp. 2280–2285, 1991, doi: 10.1161/01.CIR.84.6.2280.

S. Ishikawa et al., “Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair,” J Thorac Cardiovasc Surg, vol. 110, no. 1, pp. 271–273, Jul. 1995, doi: 10.1016/S0022-5223(05)80036-4.

S. Fuse and T. Kamiya, “Plasma thromboxane B2 concentration in pulmonary hypertension associated with congenital heart disease.,” Circulation, vol. 90, no. 6, pp. 2952–2955, 1994, doi: 10.1161/01.CIR.90.6.2952.

B. K. S. Sastry, C. Narasimhan, N. K. Reddy, and B. S. Raju, “Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study,” J Am Coll Cardiol, vol. 43, no. 7, pp. 1149–1153, Apr. 2004, doi: 10.1016/J.JACC.2003.10.056.

D. HEATH and J. E. EDWARDS, “The Pathology of Hypertensive Pulmonary Vascular Disease,” Circulation, vol. 18, no. 4 Part 1, pp. 533–547, 1958, doi: 10.1161/01.CIR.18.4.533.

A. P. Bolger et al., “Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease,” Circulation, vol. 106, no. 1, pp. 92–99, Jul. 2002, doi: 10.1161/01.CIR.0000020009.30736.3F/ASSET/E60E5B29-4D11-4BC4-94FA-D8F3546407BA/ASSETS/GRAPHIC/G21FF2.JPEG.

V. V. McLaughlin et al., “Survival with first-line bosentan in patients with primary pulmonary hypertension,” European Respiratory Journal, vol. 25, no. 2, pp. 244–249, Feb. 2005, doi: 10.1183/09031936.05.00054804.

N. Nickel et al., “The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension,” European Respiratory Journal, vol. 39, no. 3, pp. 589–596, Feb. 2012, doi: 10.1183/09031936.00092311.

O. Sitbon et al., “Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival,” J Am Coll Cardiol, vol. 40, no. 4, pp. 780–788, Aug. 2002, doi: 10.1016/S0735-1097(02)02012-0.

S. Alabed et al., “Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis,” JACC Cardiovasc Imaging, vol. 14, no. 5, pp. 931–942, May 2021, doi: 10.1016/J.JCMG.2020.08.013.

A. J. Swift et al., “Magnetic resonance imaging in the prognostic evaluation of patients with pulmonary arterial hypertension,” Am J Respir Crit Care Med, vol. 196, no. 2, pp. 228–239, Jul. 2017, doi: 10.1164/RCCM.201611-2365OC/SUPPL_FILE/DISCLOSURES.PDF.

R. A. Lewis et al., “Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension,” https://doi.org/10.1164/rccm.201909-1771OC, vol. 201, no. 4, pp. 458–466, Feb. 2020, doi: 10.1164/RCCM.201909-1771OC.

E. Grünig et al., “Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial,” Eur Heart J, vol. 42, no. 23, pp. 2284–2295, Jun. 2021, doi: 10.1093/EURHEARTJ/EHAA696.

E. Wolsk et al., “The Influence of Age on Hemodynamic Parameters During Rest and Exercise in Healthy Individuals,” JACC Heart Fail, vol. 5, no. 5, pp. 337–346, May 2017, doi: 10.1016/J.JCHF.2016.10.012.

N. Galiè et al., “Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study,” Circulation, vol. 114, no. 1, pp. 48–54, Jul. 2006, doi: 10.1161/CIRCULATIONAHA.106.630715/ASSET/B3DFDF73-0FE8-475B-8C5A-6A1986C42B72/ASSETS/GRAPHIC/12FF2.JPEG.

W. A. Zuckerman, D. Leaderer, C. A. Rowan, J. D. Mituniewicz, and E. B. Rosenzweig, “Ambrisentan for Pulmonary Arterial Hypertension Due to Congenital Heart Disease,” Am J Cardiol, vol. 107, no. 9, pp. 1381–1385, May 2011, doi: 10.1016/J.AMJCARD.2010.12.051.

H. Nashat et al., “A single-centre, placebo-controlled, double-blind randomised cross-over study of nebulised iloprost in patients with Eisenmenger syndrome: A pilot study,” Int J Cardiol, vol. 299, pp. 131–135, Jan. 2020, doi: 10.1016/J.IJCARD.2019.07.004.

M. D’Alto et al., “The effects of parenteral prostacyclin therapy as add-on treatment to oral compounds in Eisenmenger syndrome,” European Respiratory Journal, vol. 54, no. 5, Nov. 2019, doi: 10.1183/13993003.01401-2019.

K. Dimopoulos et al., “Heart or heart-lung transplantation for patients with congenital heart disease in England,” Heart, vol. 105, no. 8, pp. 596–602, Apr. 2019, doi: 10.1136/HEARTJNL-2018-313984.

M. Lankeit et al., “Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension,” The Journal of Heart and Lung Transplantation, vol. 37, no. 2, pp. 250–258, Feb. 2018, doi: 10.1016/J.HEALUN.2017.06.011.

M. Newnham et al., “CAMPHOR score: patient-reported outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension,” European Respiratory Journal, vol. 56, no. 4, Oct. 2020, doi: 10.1183/13993003.02096-2019.

M. Delcroix et al., “Long-Term Outcome of Patients with Chronic Thromboembolic Pulmonary Hypertension : Results from an International Prospective Registry,” Circulation, vol. 133, no. 9, pp. 859–871, Mar. 2016, doi: 10.1161/CIRCULATIONAHA.115.016522/-/DC1.

W. C. Hsieh, P. Jansa, W. C. Huang, M. Nižnanský, M. Omara, and J. Lindner, “Residual pulmonary hypertension after pulmonary endarterectomy: A meta-analysis,” J Thorac Cardiovasc Surg, vol. 156, no. 3, pp. 1275–1287, Sep. 2018, doi: 10.1016/J.JTCVS.2018.04.110.